Skip to content

Clinical trials

Postoperative Complications trials in Brazil

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Postoperative Complications Country / region: Brazil Clear all

36 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20081
20101
20113
20132
20142
20152
20162
20173
20182
20193
20201
20211
20224
20231
20243
20251
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed15
Unknown status12
Recruiting7
Not yet recruiting2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University of Sao Paulo6
Hospital de Clinicas de Porto Alegre4
University of Sao Paulo General Hospital4
Federal University of Minas Gerais3
Federal University of Mato Grosso2
Federal University of São Paulo2
Hospital Nossa Senhora da Conceicao2
Barretos Cancer Hospital1
Brazilian Society of Head and Neck Surgery1
Faculdade de Ciências Médicas da Santa Casa de São Paulo1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Postoperative Complications36
Inflammation2
Intraoperative Complications2
Neoplasms2
Postoperative Nausea and Vomiting2
Postoperative Pain2
Acute Kidney Injury1
Acute Pain1
Cardiovascular Diseases1
Cognitive Dysfunction1

Trials

Showing 76 to 36 of 36. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.